The 30 outpatients in advanced metastatic triple negative breast cancer showed 80% disease control, advanced pancreatic cancer with 90% control and median overall survival of 9.5 months, and advanced head and neck cancer with 67% disease control among others.
The company said their aim "is to achieve chemo-free, biologically driven immunotherapy for the early treatment and prevention of cancer beyond 2020."
Shares of NantKwest climbed 30.83% to $3.54 on Thursday. The stock closed on Wednesday up 2.26% at $2.71.
READ: IMV pours money into funding its immunotherapy cancer research; Mackie Research tags as Speculative Buy
“High dose, uninformed, toxic chemotherapy damages the immune system and induces what is known as tolerogenic cell death," said Doctor Patrick Soon-Shiong, the Chair and CEO of NantKwest.
"Natural killer cells are the core innate immuno-protective mechanism against cancer. By developing a system of activating the patient’s own natural killer cells and T cells, as well as augmenting the patient’s NK killing ability with engineering off-the-shelf NK transfusions, we hypothesize that resistant cancer can be overcome," he added.
NantKwest is a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases.
The company is based in Culver City, California.
Reporting by Rene Pastor, contactable on [email protected]